



Automating Cell-Based Assays: Reducing Variability & Time to Results

LUKE MERCER MANAGER, BIOASSAYS

©2024 CATALENT, INC. ALL RIGHTS RESERVED.

more products. better treatments. reliably supplied.™

AGENDA

1 Introduction To Catalent

Cell-Based Assays
 Variability and Automation

3 HEK293 Potency Assay





INTEGRATED & STANDALONE CDMO SOLUTIONS TO ACCELERATE YOUR BIOLOGIC TO MARKET



2

Biologics Analytical Services Single Source for Integrated & Standalone Capabilities

GMP Analytical Services

- Method development, transfer & optimization
- Phase-appropriate validation
- In-process, release & stability testing
- Binding & cell-based assays
- Extractables & leachables

GLP Support for Clinical Studies

Experience with broad classes of large molecules:

- Monoclonal, polyclonal & bispecific antibodies
- Bioconjugates & ADCs
- Oligonucleotides
- Recombinant proteins
- Fusion proteins

- Pegylated peptides
- Cell and gene therapies
- Aptamers
- Vaccines

٠

Oligosaccharides



225+ scientists across the sites

100,000+ ft³ of stability chambers

800+ assays/ techniques offered

300+ client programs supported

AGENDA

1 Introduction To Catalent

Cell-Based Assays Variability and Automation

3 HEK293 Potency Assay

4 Conclusion



Cell-Based Potency Assays



Critical to show biological activity

High potential for variability

Time consuming setup and low sample throughput

Cell-Based Potency Assays

Biological systems can result in significant variability

Ways to manage variability

- Properly written method
- Analyst training
- Tight control of cells
- Replication of reference and sample
- Plate replication
- Automation

Plate Replication Examples







Examples of Variability in Bioassays



- Shift in results between analysts
- Variability with test occasion
- Plate replicates within assay are close



- Analysts get similar results
- Test occasion does not change results
- Plate replicates show significant variability

7

Automation Advantages - Improved Safety and Efficiency

Automation of lab processes makes our workforce more efficient

- Allows analysts to multitask by reducing the time devoted to a single assay
- Hands on time reduced significantly
- Reduced ergonomic risk



Image used with permission from Hamilton

Automated Advantages - Reliable, Accurate, and Precise



- Removes person-to-person and day-to-day variability
- Does not get fatigued or distracted
- Reduces assay development time
- Faster turnaround time
- Consistent performance
- Increased reproducibility

AGENDA

Introduction To Catalent

Cell-Based Assays 2 Variability and Automation

HEK293 Potency Assay 3

Conclusion 4



HEK293 Cell-Based Assay



HEK293 Cell-Based Assay

	1	2	3	4	5	6	7	8	9	10	11	12
Α												
В	CNTL	Sam	CNTL									
C	CNTL	Ref	CNTL									
D	CNTL	Sam	CNTL									
E	CNTL	Ref	CNTL									
F	CNTL	Sam	CNTL									
G	CNTL	Ref	CNTL									
Н												
	1	2	2	1	5	6	7	0	0	10	11	12
<u> </u>	1	2	5	4	5	0	/	0	9	10	11	12
A												
B	CNTL	Ref	CNTL									
B C	CNTL CNTL	Ref Sam	CNTL CNTL									
B C D	CNTL CNTL CNTL	Ref Sam Ref	CNTL CNTL CNTL									
B C D E	CNTL CNTL CNTL CNTL	Ref Sam Ref Sam	CNTL CNTL CNTL CNTL									
B C D E F	CNTL CNTL CNTL CNTL CNTL	Ref Sam Ref Sam Ref	CNTL CNTL CNTL CNTL CNTL									
A B C D E F G	CNTL CNTL CNTL CNTL CNTL CNTL	Ref Sam Ref Sam Ref Sam	CNTL CNTL CNTL CNTL CNTL CNTL									

- Two plate assay 1 sample
- 3 10-point serial dilutions per plate
- Varied sample and reference pattern

Assay Challenges

Complete media removal twice

Three additions to all wells

Speed needed - minimize time out of incubator

Step with 20-30 minute incubation limits number of plates

Complex processing and short incubation times limit setup to 4 plates (2 samples)

Multiple aspirate and dispense steps along with semiadherence of HEK293 cells can lead to variability due to cell loss

Analysts require significant training to be able to perform

Most common assay failure is high CV between the replicate plates

Following cell-based portion analyst performs ELISAs on all plates

HEK293 Cell-Based Assay



Both plates were run at a nominal potency of 60%. Relative potencies for Plate 1 and Plate 2 were **64.2%** and **68.5%**, respectively.

Reportable value:	66.4
SD:	3.0
%CV between RPs:	4.6



Both plates were run at a nominal potency of 100%. Relative potencies for Plate 1 and Plate 2 were **102.6%** and **69.0%**, respectively.

Xaxis

Reportable value:	85.8
SD:	27.8
%CV between RPs:	27.7

0.0e0

Can We Automate This Assay?



The Bioassay Robot – HAMILTON® Microlab STAR™



Automating the Assay – Build the Deck



Labware



Location

Automating the Assay – Setup the Steps



Automating the Assay – Simulations and Water Runs



Automating the Assay – Assay



1. Initial media change manually and start incubation

2. Reference and Sample dilutions

 Formulation has some viscosity - reduce aspirate/dispense speeds, minimize depth of tips in liquid, follow liquid level

3. Cell plates

 Disruption of cells – reduce aspirate/dispense speeds, moved pipetting close to edge of wells

4. Throughput

 Set up 8 plates and start 3-5 hour step, after 3 hours process 4 and then process second 4 plates

HAMILTON[®] Microlab STAR[™] Assay Run



Both plates were run at a nominal potency of 100%. Relative potencies for Plate 1 and Plate 2 were **98.6%** and **98.8%**, respectively.

 Reportable value:
 98.7

 SD:
 0.1

 %CV between RPs:
 0.1

AGENDA

1 Introduction To Catalent

Cell-Based Assays
 Variability and Automation

3 HEK293 Potency Assay





Bioassay Automation Summary

Overview

• Advantages: safety, performance, quality

Comparisons

Manual vs. automation

Adapting to automated

• Complex steps possible





THANK YOU STOP BY BOOTH 24

LUKE MERCER MANAGER, BIOASSAYS

©2024 Catalent, inc. All rights reserved.

more products. better treatments. reliably supplied.™